Advances in the Management of Superficial Bladder Cancer

Seminars in Oncology

Volumn 34, Issue 2, 2007, Pages 85-97

  O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; IMMUNOMODULATING AGENT; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CLINICAL FEATURE; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EARLY DIAGNOSIS; FLUORESCENCE; HIGH RISK PATIENT; HUMAN; HYPERTHERMIC THERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; TECHNOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33947270826     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.12.012     Document Type: Article

References (111)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2007. CA Cancer J Clin 57 (2007) 43-66
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2006) 74-108
3. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
4. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 66 suppl 1 (2005) 4-34
5. Travis L.B., Curtis R.E., and Glimelius B. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87 (1995) 524-530
6. Nortier J.L., Martinez M.C., Schmeiser H.H., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342 (2000) 1686-1692
7. Karagas M.R., Tosteson T.D., Morris J.S., et al. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control 15 (2004) 465-472
8. Weyer P.J., Cerhan J.R., Kross B.C., et al. Municipal drinking water nitrate level and cancer risk in older women: The Iowa Women's Health Study. Epidemiology 12 (2001) 327-338
9. Aben K.K., Witjes J.A., Schoenberg M.P., et al. Familial aggregation of urothelial cell carcinoma. Int J Cancer 98 (2002) 274-278
10. Kiemeney L.A., Kuiper R.P., Pfundt R., et al. No evidence for large-scale germline genomic aberrations in hereditary bladder cancer patients with high-resolution array-based comparative genomic hybridization. Cancer Epidemiol Biomarkers Prev 15 (2006) 180-183
11. Garcia-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
12. Grignon D.J., Shum D.T., and Bruckschwaiger O. Transitional cell carcinoma in the Muir-Torre syndrome. J Urol 138 (1987) 406-408
13. O'Donnell M.A., Lilli K., and Leopold C. Contemporary profile of superficial bladder cancer revealed from an open-entry national multicenter study. J Urol 171 suppl (2004) 283A (abstr)
14. Wijkstrom H., Cohen S.M., Gardiner R.A., et al. Prevention and treatment of urothelial premalignant and malignant lesions. Scand J Urol Nephrol 205 suppl (2000) 116-135
15. Bassi P., De Marco V., De Lisa A., et al. Non-invasive diagnostic tests for bladder cancer: A review of the literature. Urol Int 75 (2005) 193-200
16. Amiel G.E., Shu T., and Lerner S.P. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Curr Treat Options Oncol 5 (2004) 377-389
17. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-816
18. Grossman H.B., Soloway M., Messing E., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295 (2006) 299-305
19. Boman H., Hedelin H., and Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. Urol 167 (2002) 80-83
20. van Rhijn B.W., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 47 (2005) 736-748
21. Glas A.S., Roos D., Deutekom M., et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 169 (2003) 1975-1982
22. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analysis. Urology 61 (2003) 109-118
23. Smith S.D., Wheeler M.A., Plescia J., et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
24. Sanchini M.A., Gunelli R., Bravaccini S., et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294 (2005) 2052-2056
25. Sorensen F.B., Sasaki M., Fukuzawa S., et al. Qualitative and quantitative histopathology in transitional cell carcinomas of the urinary bladder. An international investigation of intra- and interobserver reproducibility. Lab Invest 70 (1994) 242-254
26. Heney N.M. Natural history of superficial bladder cancer: Prognostic features and long-term disease course. Urol Clin North Am 19 (1992) 429-433
27. Kurth K.H., Denis L., Bouffioux C., et al. Factors affecting recurrence and progression in superficial bladder cancer. Eur J Cancer 31A (1995) 1840-1846
28. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466
29. Holmang S., Hedelin H., Anderstrom C., et al. The relationship among multiple recurrences, progression and prognosis in patients with stage Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years. J Urol 153 (1995) 1823-1827
30. Fitzpatrick J.M., West A.B., and Butler M.R. Superficial bladder tumors: The importance of recurrence pattern following initial resection. J Urol 135 (1986) 920-924
31. Williams S.G., Buscarini M., and Stein J.P. Molecular markers for diagnosis, staging, and prognosis of bladder cancer. Oncology 15 (2001) 1461-1470
32. Brauers A., Buettner R., and Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?. J Urol 165 (2001) 808-810
33. Jakse G., Algaba F., Malmstrom P.U., et al. A second-look TUR in T1 transitional cell carcinoma: Why?. Eur Urol 45 (2004) 539-546
34. Sanchez-Chapado M., Angulo J.C., Hontoria H., et al. [Staging error in bladder carcinoma: Anatomo-clinical correlation]. Actas Urol Esp 19 (1995) 32-39
35. Kamat A.M., Gee J.R., Dinney C.P., et al. The case for early cystectomy in non-muscle invasive micropapillary transitional cell carcinoma of the bladder. J Urol 173 suppl (2005) 915A (abstr)
36. Siefker-Radtke A.O., Dinney C.P., Abrahams N.A., et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: A retrospective review of the M.D. Anderson cancer experience. J Urol 172 (2004) 481-484
37. Lee C.T., Montie J.E., Zhang Y.X., et al. Lymphovascular invasion is an independent predictor of survival in cT1 bladder cancer. J Urol 173 suppl (2005) 911A (abstr)
38. Lamm D.L., and Griffith J.G. Intravesical therapy: Does it affect the natural history of superficial bladder cancer?. Semin Urol 10 (1992) 39-44
39. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 174 (2005) 862-866
40. Riedl C.R., Daniltchenko D., Koenig F., et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165 (2001) 1121-1123
41. Babjuk M., Soukup V., Petrik R., et al. 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 96 (2005) 798-802
42. Filbeck T., Roessler W., Knuechel R., et al. 5-Aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology 53 (1999) 77-81
43. Trkova M., Babjuk M., Duskova J., et al. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. Cancer Lett 242 (2005) 68-76
44. Soloway M.S., Nissenkorn I., and McCallum L. Urothelial susceptibility to tumor cell implantation: Comparison of cauterization with N-methyl-N-nitrosourea. Urology 21 (1983) 159-161
45. Kaasinen E., Rintala E., Hellstrom P., et al., FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174
46. Hinotsu S., Akaza H., Ohashi Y., et al. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86 (1999) 1818-1826
47. Goto K., Konomoto T., Hayashi K., et al. p53 mutations in multiple urothelial carcinomas: A molecular analysis of the development of multiple carcinomas. Mod Pathol 10 (1997) 428-437
48. Traynelis C.L., and Lamm D.L. Current status of intravesical therapy for bladder cancer. In: Rous S.N. (Ed). Urology Annual vol 8 (1994), Norton, New York, NY 113-143
49. Lamm D.L., Riggs D.R., Ttaynelis C.L., et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153 (1995) 1444-1450
50. Huncharek M., McGarry R., and Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: Results of a meta-analysis. Anticancer Res 21 (2001) 765-769
51. O'Donnell M.A. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am 32 (2005) 121-131
52. Thrasher J.B., and Crawford E.D. Complications of intravesical chemotherapy. Urol Clin North Am 19 (1992) 529-539
53. Bouffioux C., Denis L., Oosterlinck W., et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. J Urol 148 (1992) 297-301
54. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20 (2002) 3193-3198
55. Bartoletti R., Cai T., Gacci M., et al., TUR (Toscana Urologia) Group. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a phase II prospective multicenter study. Urology 66 (2005) 726-731
56. McKiernan J.M., Murphy A.M., Goetzl M., et al. Phase I trial intravesical docetaxel (Taxotere) for recurrent superficial bladder cancer (2005) Program and abstracts of the American Urological Association Annual Meeting, San Antonio, TX, May 21-26, (abstr 916)
57. Sekine H., Ohya K., Kojima S.I., et al. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. Int J Urol 8 (2001) 483-486
58. Maymi J.L., Saltsgaver N., and O'Donnell M.A. Intravesical sequential chemotherapy for patients at high risk with refractory superficial bladder cancer. J Urol 174 suppl (2006) 271 (abstr 840)
59. Au J.L., Badalament R.A., Wientjes M.G., et al., International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597-604
60. Colombo R., Da Pozzo L.F., Salonia A., et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21 (2003) 4270-4276
61. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study. J Urol 170 (2003) 777-782
62. Kavoussi L.R., Torrence R.J., Gillen D.P., et al. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol 139 (1988) 935-940
63. Sylvester R.J., van der Meidjen A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
64. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
65. Huncharek M., and Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation. Am J Clin Oncol 26 (2003) 402-407
66. Shelley M.D., Wilt T.J., Court J., et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
67. Bohle A., and Bock P.R. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-686
68. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-91
69. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance BCG immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
70. Thalmann G.N., Sermier A., Rentsch C., et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164 (2000) 2129-2133
71. Watanabe E., Matsuyama H., Matsuda K., et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52 (2003) 481-486
72. Saint F., Patard J.J., Maille P., et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 167 (2002) 364-367
73. Ludwig A.T., Moore J.M., Luo Y., et al. Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64 (2004) 3386-3390
74. Leibovici D., Grossman H.B., Dinney C.P., et al. Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival. J Clin Oncol 23 (2005) 5746-5456
75. Lamm D.L., Steg A., Boccon-Gibad L., et al. Complications of bacillus Calmette-Guerin immunotherapy: Review of 2,602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 310 (1989) 335
76. Steg A., Leleu C., Debre B., et al. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 310 (1989) 325-334
77. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al., Club Urologico Espanol de Tratamiento Oncologico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?. Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
78. Pagano F., Bassi P., Piazza N., et al. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 27 (1995) 19-22 (suppl 1)
79. Morales A., Nickel J.C., and Wilson J.W. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 147 (1992) 1256-1258
80. Andius P., Fehrling M., and Holmang S. Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96 (2005) 1290-1293
81. Bassi P., Spinadin R., Carando R., et al. Modified induction course: A solution to side-effects?. Eur Urol 37 suppl 1 (2000) 31-32
82. Belldegrun A.S., Franklin J.R., O'Donnell M.A., et al. Superficial bladder cancer: The role of interferon-alpha. J Urol 159 (1998) 1793-1801
83. Ficarra V., Dalpiaz O., Alrabi N., et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95 (2005) 786-790
84. May M., Helke C., Nitzke T., et al. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int 72 (2004) 103-111
85. Stein J.P. Indications for early cystectomy. Urology 62 (2003) 591-595
86. Harland S.J., and UK NCRI Bladder Clinical Studies Group. A randomized trial of radical radiotherapy in pT1G3 NXM0 bladder cancer (MRC BS06). J Clin Oncol 23 (2005) S16 (abstr 4505)
87. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66 suppl 1 (2005) 108-125
88. Thalmann G.N., Markwalder R., Shahin O., et al. Primary T1G3 bladder cancer: Organ preserving approach or immediate cystectomy?. J Urol 172 (2004) 70-75
89. Herr H.W., Badalament R.A., Amato D.A., et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression. J Urol 141 (1989) 22-29
90. Catalona W.J., Hudson M.A., Gillen D.P., et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137 (1987) 220-224
91. Huguet J., Crego M., Sabate S., et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48 (2005) 53-59
92. Bui T.T., and Schellhammer P.F. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49 (1997) 687-690
93. Orsola A., Trias I., Raventos C.X., et al. Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48 (2005) 231-238
94. Kipp B.R., Karnes R.J., Brankley S.M., et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173 (2005) 401-404
95. Lacombe L., Dalbagni G., Zhang Z.F., et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome. J Clin Oncol 14 (1996) 2646-2652
96. Prout Jr. G.R., Wesley M.N., Yancik R., et al. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: A population-based study. Cancer 104 (2005) 1638-1647
97. Malmstrom P.U., Wijkstrom H., Lundholm C., et al., Swedish-Norwegian Bladder Cancer Study Group. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 161 (1999) 1124-1127
98. Steinberg G., Bahnson R., Brosman S., et al., The Valrubicin Study Group. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol 163 (2000) 761-767
99. van der Heijden A.G., Kiemeney L.A., Gofrit O.N., et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46 (2004) 65-71
100. O'Donnell M.A., Krohn J., and DeWolf W.C. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166 (2001) 1300-1304
101. Joudi F.N., Smith B.J., O'Donnell M.A., et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
102. Akcetin Z., Todorov J., Tuzel E., et al. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer. Anticancer Res 25 (2005) 1623-1628
103. Nseyo U.O., Shumaker B., Klein E.A., et al., Bladder Photofrin Study Group. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol 160 (1998) 39-44
104. Marti A., Jichlinski P., Lange N., et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 170 (2003) 428-432
105. Schwalb M.D., Herr H.W., Sogani P.C., et al. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: Pattern of recurrence. J Urol 152 (1994) 382-387
106. Morgan J.D., Bowsher W., Griffiths D.F., et al. Rationalization of follow-up in patients with non-invasive bladder tumors. Br J Urol 72 (1993) 135-142
107. Fleshner N., Garland J., Moadel A., et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 86 (1999) 2337-2345
108. Lamm D.L., Riggs D.R., Shriver J.S., et al. Megadose vitamins in bladder cancer: A double-blind clinical trial. J Urol 151 (1994) 21-26
109. Pruthi R.S., Derksen E., Gaston K., et al. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology 64 (2004) 637-642
110. Lerner S.P., Sabichi A.L., Grossman H.B., et al. Results of a randomized chemoprevention trial with finretinide in non-muscle invasive bladder cancer. J Urol 173 suppl (2005) 913A (abstr)
111. Messing E.M., Kim K.M., Wilding G., et al. A randomized prospective phase II trial of difluoromethylornithine (DFMO) vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 173 suppl (2005) 922A (abstr)